ReviewClinical rheumatology2019
Infliximab for the treatment of refractory polyarteritis nodosa.
Review in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Clinical presentations and long term prognosis of childhood onset polyarteritis nodosa in single centre of Korea.Scientific reports · 2021Trial
- Thrombosis in vasculitis: An updated review of etiology, pathophysiology, and treatment.Heliyon · 2024Review
- Article
- Efficacy of rituximab in refractory polyarteritis nodosa: a case report.The Pan African medical journal · 2023Article
- Recent Advances in Pediatric Vasculitis.Rheumatic diseases clinics of North America · 2021Review
- Coexistence of Polyarteritis Nodosa of the Vulva and Retina in a Behçet's Disease Patient: A Case Report.Cureus · 2021Article
- Vasculitis: From Target Molecules to Novel Therapeutic Approaches.Biomedicines · 2021Review
- Safe and successful treatment of refractory polyarteritis nodosa with tocilizumab in a patient with past hepatitis B virus infection: a case-based review.Clinical rheumatology · 2021Review
- Clinical Approach to Diagnosis and Therapy of Polyarteritis Nodosa.Current rheumatology reports · 2021Review
- Human hepatitis viruses-associated cutaneous and systemic vasculitis.World journal of gastroenterology · 2021Review
- Endovascular Biopsy of Vertebrobasilar Aneurysm in Patient With Polyarteritis Nodosa.Frontiers in neurology · 2021Article
- Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart.Clinical immunology (Orlando, Fla.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyarteritis nodosa (PAN) is a necrotizing vasculitis predominantly affecting medium and small size arteries. Cyclophosphamide, a drug with narrow therapeutic range and poor safety profile, constitutes the treatment of choice for PAN vasculitis with major organ involvement. To describe our clinical experience in treating refractory PAN with infliximab (a TNF inhibitor), a drug with good tolerability and better safety profile than cyclophosphamide. Twenty-six PAN patients were admitted to our rheumatology unit between 2006 and 2017, of whom nine patients, with severe and refractory disease, were treated with infliximab after failure of standard treatment. We describe herein the patients' characteristics, clinical manifestations, severity and response to infliximab treatment and review the current literature. Complete remission was defined as the absence of features of active disease and withdrawal of prednisone therapy. Significant improvement was defined as clinical improvement and prednisone dose reduction of at least 50% or a 50% reduction in immune modulatory medications other than prednisone. After 4 months of treatment, 8/9 (89%) patients achieved significant improvement, with two of them achieving complete remission. We suggest that anti-TNF agents, and in particular infliximab, are relatively safe and efficacious treatment options in refractory PAN. A randomized controlled trial should be done in order to objectively evaluate infliximab in PAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.